Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01382498|
Recruitment Status : Unknown
Verified April 2011 by Tabriz University.
Recruitment status was: Enrolling by invitation
First Posted : June 27, 2011
Last Update Posted : June 27, 2011
|Condition or disease||Intervention/treatment||Phase|
|Diabetic Retinopathy||Drug: Calcium dobesilate (Doxium) Drug: Placebo drug||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Study Start Date :||November 2009|
|Estimated Primary Completion Date :||June 2011|
Placebo Comparator: Placebo
Placebo tablets will be administered to the patients in Placebo arms daily for three months.
Drug: Placebo drug
Similar to the that of the Experimental arm, Daily, Three months
Experimental: Calcium dobesilate
Calcium dobesilate as 500 mg tablets will be administered once to the patients daily.
Drug: Calcium dobesilate (Doxium)
500 mg, Tablet, Daily, 3 months
- high sensitivity CRP and Endothelin-1 serum levels [ Time Frame: 3 month ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01382498
|Iran, Islamic Republic of|
|Tabriz University of Medical Sciences|
|Tabriz, Eastern Azerbayjan, Iran, Islamic Republic of, 5137874976|